(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
4.40% $ 10.57
@ $7.33
Выпущен: 14 февр. 2024 @ 21:17
Доходность: 44.20%
Предыдущий сигнал: февр. 14 - 17:30
Предыдущий сигнал:
Доходность: 6.23 %
Live Chart Being Loaded With Signals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases...
Stats | |
---|---|
Объем за сегодня | 193 217 |
Средний объем | 475 155 |
Рыночная капитализация | 273.83M |
EPS | $0 ( 2024-03-06 ) |
Дата следующего отчета о доходах | ( $-1.080 ) 2024-05-08 |
Last Dividend | $0.0690 ( 2017-09-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.740 |
ATR14 | $0.0200 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Sell | 972 | Restricted Stock Unit |
2024-02-26 | Weiner David B. | Sell | 972 | Restricted Stock Unit |
INSIDER POWER |
---|
61.43 |
Last 100 transactions |
Buy: 3 683 868 | Sell: 932 723 |
Объем Корреляция
Inovio Pharmaceuticals Корреляция
10 Самые положительные корреляции | |
---|---|
AKTX | 0.966 |
LSXMA | 0.961 |
LSXMK | 0.961 |
STRO | 0.95 |
TUEM | 0.948 |
ASPU | 0.946 |
OPHC | 0.943 |
CMLS | 0.942 |
WATT | 0.942 |
AADI | 0.941 |
10 Самые отрицательные корреляции | |
---|---|
CPTA | -0.952 |
SGEN | -0.946 |
RAM | -0.936 |
GPACU | -0.936 |
NVSA | -0.936 |
COCO | -0.934 |
MLAI | -0.932 |
PESI | -0.928 |
PTOC | -0.928 |
FRSG | -0.927 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Inovio Pharmaceuticals Корреляция - Валюта/Сырье
Inovio Pharmaceuticals Финансовые показатели
Annual | 2023 |
Выручка: | $832 010 |
Валовая прибыль: | $-2.67M (-321.09 %) |
EPS: | $-6.09 |
FY | 2023 |
Выручка: | $832 010 |
Валовая прибыль: | $-2.67M (-321.09 %) |
EPS: | $-6.09 |
FY | 2022 |
Выручка: | $10.26M |
Валовая прибыль: | $4.77M (46.44 %) |
EPS: | $-14.47 |
FY | 2021 |
Выручка: | $1.77M |
Валовая прибыль: | $0.00 (0.00 %) |
EPS: | $-1.450 |
Financial Reports:
No articles found.
Inovio Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0690 | 2017-06-28 |
Last Dividend | $0.0690 | 2017-09-28 |
Next Dividend | $0 | N/A |
Payout Date | 2017-10-16 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | $0.276 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.17 | -- |
Div. Sustainability Score | 2.18 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.449 | -- |
Year | Amount | Yield |
---|---|---|
2017 | $0.276 | 3.90% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 3 430.55 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 16.50 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 18.29 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.60 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.47 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.336 | 1.500 | 9.24 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.175 | -1.500 | 7.09 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -241.59 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -5.80 | 2.00 | -1.932 | -3.86 | [0 - 30] |
freeCashFlowPerShareTTM | -5.81 | 2.00 | -2.90 | -5.81 | [0 - 20] |
debtEquityRatioTTM | 0.257 | -1.500 | 8.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -38.10 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -173.00 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -4.37 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00481 | 0.800 | -3.30 | -2.64 | [0.5 - 2] |
Total Score | 2.18 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0.0844 | 1.000 | -0.0925 | 0 | [1 - 100] |
returnOnEquityTTM | 18.29 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -5.81 | 2.00 | -1.936 | -5.81 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -5.80 | 2.00 | -1.932 | -3.86 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0000652 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -158.77 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.283 |
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа